Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1849 to 1856 of 1856 entries
Sorted by: Best Match Show Resources per page
Clionamines stimulate autophagy, inhibit Mycobacterium tuberculosis survival in macrophages, and target Pik1.

Cell chemical biology

Persaud R, Li SC, Chao JD, Forestieri R, Donohue E, Balgi AD, Zheng X, Chao JT, Yashiroda Y, Yoshimura M, Loewen CJR, Gingras AC, Boone C, Av-Gay Y, Roberge M, Andersen RJ.
PMID: 34520745
Cell Chem Biol. 2021 Sep 11; doi: 10.1016/j.chembiol.2021.07.017. Epub 2021 Sep 11.

The pathogen Mycobacterium tuberculosis (Mtb) evades the innate immune system by interfering with autophagy and phagosomal maturation in macrophages, and, as a result, small molecule stimulation of autophagy represents a host-directed therapeutics (HDTs) approach for treatment of tuberculosis (TB)....

Cite
Persaud R, Li SC, Chao JD, et al. Clionamines stimulate autophagy, inhibit Mycobacterium tuberculosis survival in macrophages, and target Pik1. Cell Chem Biol. 2021;doi: 10.1016/j.chembiol.2021.07.017.
Persaud, R., Li, S. C., Chao, J. D., Forestieri, R., Donohue, E., Balgi, A. D., Zheng, X., Chao, J. T., Yashiroda, Y., Yoshimura, M., Loewen, C. J. R., Gingras, A. C., Boone, C., Av-Gay, Y., Roberge, M., & Andersen, R. J. (2021). Clionamines stimulate autophagy, inhibit Mycobacterium tuberculosis survival in macrophages, and target Pik1. Cell chemical biology, . https://doi.org/10.1016/j.chembiol.2021.07.017
Persaud, Rosanne, et al. "Clionamines stimulate autophagy, inhibit Mycobacterium tuberculosis survival in macrophages, and target Pik1." Cell chemical biology vol. (2021). doi: https://doi.org/10.1016/j.chembiol.2021.07.017
Persaud R, Li SC, Chao JD, Forestieri R, Donohue E, Balgi AD, Zheng X, Chao JT, Yashiroda Y, Yoshimura M, Loewen CJR, Gingras AC, Boone C, Av-Gay Y, Roberge M, Andersen RJ. Clionamines stimulate autophagy, inhibit Mycobacterium tuberculosis survival in macrophages, and target Pik1. Cell Chem Biol. 2021 Sep 11; doi: 10.1016/j.chembiol.2021.07.017. Epub 2021 Sep 11. PMID: 34520745.
Copy Download .nbib Format: NLM
In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi

Liu PY, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, Lu MC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Shao PL, Lee YL, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Hsueh PR.
PMID: 34521591
J Microbiol Immunol Infect. 2021 Sep 04; doi: 10.1016/j.jmii.2021.08.012. Epub 2021 Sep 04.

BACKGROUND/PURPOSE: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics.METHODS: In total, 405 non-duplicate bacteremic...

Cite
Liu PY, Ko WC, Lee WS, et al. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020. J Microbiol Immunol Infect. 2021;doi: 10.1016/j.jmii.2021.08.012.
Liu, P. Y., Ko, W. C., Lee, W. S., Lu, P. L., Chen, Y. H., Cheng, S. H., Lu, M. C., Lin, C. Y., Wu, T. S., Yen, M. Y., Wang, L. S., Liu, C. P., Shao, P. L., Lee, Y. L., Shi, Z. Y., Chen, Y. S., Wang, F. D., Tseng, S. H., Lin, C. N., Chen, Y. H., Sheng, W. H., Lee, C. M., Tang, H. J., & Hsueh, P. R. (2021). In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, . https://doi.org/10.1016/j.jmii.2021.08.012
Liu, Po-Yu, et al. "In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020." Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi vol. (2021). doi: https://doi.org/10.1016/j.jmii.2021.08.012
Liu PY, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, Lu MC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Shao PL, Lee YL, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Hsueh PR. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020. J Microbiol Immunol Infect. 2021 Sep 04; doi: 10.1016/j.jmii.2021.08.012. Epub 2021 Sep 04. PMID: 34521591.
Copy Download .nbib Format: NLM
Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway.

Cancer biology & therapy

Wang XL, Lu SC, Sun C, Jin WG, Fan YW, Shu YS, Shi HC, Min LF.
PMID: 33970779
Cancer Biol Ther. 2021 Apr 03;22(4):324-332. doi: 10.1080/15384047.2021.1902912. Epub 2021 May 10.

Evidence suggests that Tripartite Motif Containing 11 (TRIM11) has pro-tumor activity in human non-small cell lung cancer (NSCLC). However, the roles and underlying mechanisms of TRIM11 in NSCLC have not yet been fully elucidated. In this work, human lung...

Cite
Wang XL, Lu SC, Sun C, et al. Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway. Cancer Biol Ther. 2021;22(4):324-332doi: 10.1080/15384047.2021.1902912.
Wang, X. L., Lu, S. C., Sun, C., Jin, W. G., Fan, Y. W., Shu, Y. S., Shi, H. C., & Min, L. F. (2021). Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway. Cancer biology & therapy, 22(4), 324-332. https://doi.org/10.1080/15384047.2021.1902912
Wang, Xiao-Lin, et al. "Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway." Cancer biology & therapy vol. 22,4 (2021): 324-332. doi: https://doi.org/10.1080/15384047.2021.1902912
Wang XL, Lu SC, Sun C, Jin WG, Fan YW, Shu YS, Shi HC, Min LF. Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway. Cancer Biol Ther. 2021 Apr 03;22(4):324-332. doi: 10.1080/15384047.2021.1902912. Epub 2021 May 10. PMID: 33970779; PMCID: PMC8183509.
Copy Download .nbib Format: NLM
Risk of dementia in colorectal cancer patients receiving chemotherapy: A nationwide cohort study.

Cancer epidemiology

Chiu RH, Lu SR, Liang FW, Lin CL, Ho CH, Hsiao PC.
PMID: 34920341
Cancer Epidemiol. 2021 Dec 15;76:102083. doi: 10.1016/j.canep.2021.102083. Epub 2021 Dec 15.

BACKGROUND: Studies have reported conflicting evidence regarding whether chemotherapy leads to dementia. This study aimed to determine whether chemotherapy increases dementia risk in Taiwanese patients with colorectal cancer (CRC).METHODS: Data from the Taiwan Cancer Registry and National Health Insurance...

Cite
Chiu RH, Lu SR, Liang FW, et al. Risk of dementia in colorectal cancer patients receiving chemotherapy: A nationwide cohort study. Cancer Epidemiol. 2021;76:102083doi: 10.1016/j.canep.2021.102083.
Chiu, R. H., Lu, S. R., Liang, F. W., Lin, C. L., Ho, C. H., & Hsiao, P. C. (2021). Risk of dementia in colorectal cancer patients receiving chemotherapy: A nationwide cohort study. Cancer epidemiology, 76102083. https://doi.org/10.1016/j.canep.2021.102083
Chiu, Ru-Huang, et al. "Risk of dementia in colorectal cancer patients receiving chemotherapy: A nationwide cohort study." Cancer epidemiology vol. 76 (2021): 102083. doi: https://doi.org/10.1016/j.canep.2021.102083
Chiu RH, Lu SR, Liang FW, Lin CL, Ho CH, Hsiao PC. Risk of dementia in colorectal cancer patients receiving chemotherapy: A nationwide cohort study. Cancer Epidemiol. 2021 Dec 15;76:102083. doi: 10.1016/j.canep.2021.102083. Epub 2021 Dec 15. PMID: 34920341.
Copy Download .nbib Format: NLM
Coronavirus disease 2019 (COVID-19): diagnosis and prognosis.

Blood and genomics

Wang X, Zhou Y, Liu L, Ma J, Wu H, Zhao L, Chen W, Li SC, Ran Q, Li Z.
PMID: 33768219
Blood Genom. 2020;4(2):96-107. doi: 10.46701/BG.2020022020120.

Coronavirus disease 2019 (COVID-19) has become a global pandemic with a high rate of transmission. Currently, there is a lack of vaccines and specific drugs for this newly-emerged virus. Timely diagnosis and treatment, as well as isolation of patients...

Cite
Wang X, Zhou Y, Liu L, et al. Coronavirus disease 2019 (COVID-19): diagnosis and prognosis. Blood Genom. 2020;4(2):96-107doi: 10.46701/BG.2020022020120.
Wang, X., Zhou, Y., Liu, L., Ma, J., Wu, H., Zhao, L., Chen, W., Li, S. C., Ran, Q., & Li, Z. (2020). Coronavirus disease 2019 (COVID-19): diagnosis and prognosis. Blood and genomics, 4(2), 96-107. https://doi.org/10.46701/BG.2020022020120
Wang, Xueying, et al. "Coronavirus disease 2019 (COVID-19): diagnosis and prognosis." Blood and genomics vol. 4,2 (2020): 96-107. doi: https://doi.org/10.46701/BG.2020022020120
Wang X, Zhou Y, Liu L, Ma J, Wu H, Zhao L, Chen W, Li SC, Ran Q, Li Z. Coronavirus disease 2019 (COVID-19): diagnosis and prognosis. Blood Genom. 2020;4(2):96-107. doi: 10.46701/BG.2020022020120. PMID: 33768219; PMCID: PMC7990318.
Copy Download .nbib Format: NLM
Bacterial Signatures of Paediatric Respiratory Disease: An Individual Participant Data Meta-Analysis.

Frontiers in microbiology

Broderick DTJ, Waite DW, Marsh RL, Camargo CA, Cardenas P, Chang AB, Cookson WOC, Cuthbertson L, Dai W, Everard ML, Gervaix A, Harris JK, Hasegawa K, Hoffman LR, Hong SJ, Josset L, Kelly MS, Kim BS, Kong Y, Li SC, Mansbach JM, Mejias A, O'Toole GA, Paalanen L, Pérez-Losada M, Pettigrew MM, Pichon M, Ramilo O, Ruokolainen L, Sakwinska O, Seed PC, van der Gast CJ, Wagner BD, Yi H, Zemanick ET, Zheng Y, Pillarisetti N, Taylor MW.
PMID: 35002989
Front Microbiol. 2021 Dec 23;12:711134. doi: 10.3389/fmicb.2021.711134. eCollection 2021.

No abstract available.

Cite
Broderick DTJ, Waite DW, Marsh RL, et al. Bacterial Signatures of Paediatric Respiratory Disease: An Individual Participant Data Meta-Analysis. Front Microbiol. 2021;12:711134doi: 10.3389/fmicb.2021.711134.
Broderick, D. T. J., Waite, D. W., Marsh, R. L., Camargo, C. A., Cardenas, P., Chang, A. B., Cookson, W. O. C., Cuthbertson, L., Dai, W., Everard, M. L., Gervaix, A., Harris, J. K., Hasegawa, K., Hoffman, L. R., Hong, S. J., Josset, L., Kelly, M. S., Kim, B. S., Kong, Y., Li, S. C., Mansbach, J. M., Mejias, A., O'Toole, G. A., Paalanen, L., Pérez-Losada, M., Pettigrew, M. M., Pichon, M., Ramilo, O., Ruokolainen, L., Sakwinska, O., Seed, P. C., van der Gast, C. J., Wagner, B. D., Yi, H., Zemanick, E. T., Zheng, Y., Pillarisetti, N., & Taylor, M. W. (2021). Bacterial Signatures of Paediatric Respiratory Disease: An Individual Participant Data Meta-Analysis. Frontiers in microbiology, 12711134. https://doi.org/10.3389/fmicb.2021.711134
Broderick, David T J, et al. "Bacterial Signatures of Paediatric Respiratory Disease: An Individual Participant Data Meta-Analysis." Frontiers in microbiology vol. 12 (2021): 711134. doi: https://doi.org/10.3389/fmicb.2021.711134
Broderick DTJ, Waite DW, Marsh RL, Camargo CA, Cardenas P, Chang AB, Cookson WOC, Cuthbertson L, Dai W, Everard ML, Gervaix A, Harris JK, Hasegawa K, Hoffman LR, Hong SJ, Josset L, Kelly MS, Kim BS, Kong Y, Li SC, Mansbach JM, Mejias A, O'Toole GA, Paalanen L, Pérez-Losada M, Pettigrew MM, Pichon M, Ramilo O, Ruokolainen L, Sakwinska O, Seed PC, van der Gast CJ, Wagner BD, Yi H, Zemanick ET, Zheng Y, Pillarisetti N, Taylor MW. Bacterial Signatures of Paediatric Respiratory Disease: An Individual Participant Data Meta-Analysis. Front Microbiol. 2021 Dec 23;12:711134. doi: 10.3389/fmicb.2021.711134. eCollection 2021. PMID: 35002989; PMCID: PMC8733647.
Copy Download .nbib Format: NLM
Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis.

Medicine

Wang Y, Jiang DQ, Lu CS, Li MX, Jiang LL.
PMID: 34871213
Medicine (Baltimore). 2021 Nov 05;100(44):e27511. doi: 10.1097/MD.0000000000027511.

BACKGROUND: Pramipexole (P) or levodopa (L) treatment has been suggested as a therapeutic method for Parkinson disease (PD) in many clinical studies. Nonetheless, the combined effects of 2 drugs for PD patients are not completely understood.The aim of this...

Cite
Wang Y, Jiang DQ, Lu CS, et al. Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(44):e27511doi: 10.1097/MD.0000000000027511.
Wang, Y., Jiang, D. Q., Lu, C. S., Li, M. X., & Jiang, L. L. (2021). Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis. Medicine, 100(44), e27511. https://doi.org/10.1097/MD.0000000000027511
Wang, Yan, et al. "Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis." Medicine vol. 100,44 (2021): e27511. doi: https://doi.org/10.1097/MD.0000000000027511
Wang Y, Jiang DQ, Lu CS, Li MX, Jiang LL. Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis. Medicine (Baltimore). 2021 Nov 05;100(44):e27511. doi: 10.1097/MD.0000000000027511. PMID: 34871213; PMCID: PMC8568447.
Copy Download .nbib Format: NLM
Probing layered structures by multi-color backscattering polarimetry and machine learning.

Biomedical optics express

Zhu Y, Dong Y, Yao Y, Si L, Liu Y, He H, Ma H.
PMID: 34457417
Biomed Opt Express. 2021 Jun 23;12(7):4324-4339. doi: 10.1364/BOE.425614. eCollection 2021 Jul 01.

Polarization imaging can quantitatively probe the characteristic microstructural features of biological tissues non-invasively. In biomedical tissues, layered structures are common. Superposition of two simple layers can result in a complex Mueller matrix, and multi-color backscattering polarimetry can help to...

Cite
Zhu Y, Dong Y, Yao Y, et al. Probing layered structures by multi-color backscattering polarimetry and machine learning. Biomed Opt Express. 2021;12(7):4324-4339doi: 10.1364/BOE.425614.
Zhu, Y., Dong, Y., Yao, Y., Si, L., Liu, Y., He, H., & Ma, H. (2021). Probing layered structures by multi-color backscattering polarimetry and machine learning. Biomedical optics express, 12(7), 4324-4339. https://doi.org/10.1364/BOE.425614
Zhu, Yuanhuan, et al. "Probing layered structures by multi-color backscattering polarimetry and machine learning." Biomedical optics express vol. 12,7 (2021): 4324-4339. doi: https://doi.org/10.1364/BOE.425614
Zhu Y, Dong Y, Yao Y, Si L, Liu Y, He H, Ma H. Probing layered structures by multi-color backscattering polarimetry and machine learning. Biomed Opt Express. 2021 Jun 23;12(7):4324-4339. doi: 10.1364/BOE.425614. eCollection 2021 Jul 01. PMID: 34457417; PMCID: PMC8367275.
Copy Download .nbib Format: NLM
Showing 1849 to 1856 of 1856 entries